Mesoblast Ltd
ASX:MSB

Watchlist Manager
Mesoblast Ltd Logo
Mesoblast Ltd
ASX:MSB
Watchlist
Price: 1.845 AUD -1.86% Market Closed
Market Cap: 2.3B AUD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

MSB Price Targets Summary
Mesoblast Ltd

Wall Street analysts forecast MSB stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MSB is 2.958 AUD with a low forecast of 2.424 AUD and a high forecast of 3.57 AUD.

MSB Lowest Forecast
Wall Street Target
2.424 AUD
31% Upside
MSB Average Forecast
Wall Street Target
2.958 AUD
60% Upside
MSB Highest Forecast
Wall Street Target
3.57 AUD
93% Upside
Lowest
Price Target
2.424 AUD
31% Upside
Average
Price Target
2.958 AUD
60% Upside
Highest
Price Target
3.57 AUD
93% Upside
Mesoblast Ltd Competitors:
Price Targets
J
7774
Japan Tissue Engineering Co Ltd
85% Upside
D
DVYSR
Devyser Diagnostics AB
64% Upside
2256
Abbisko Cayman Ltd
46% Upside
NRIX
Nurix Therapeutics Inc
171% Upside
J
7774
Japan Tissue Engineering Co Ltd
85% Upside
D
DVYSR
Devyser Diagnostics AB
64% Upside
2256
Abbisko Cayman Ltd
46% Upside
NRIX
Nurix Therapeutics Inc
171% Upside
BIOCON
Biocon Ltd
24% Upside
NVAX
Novavax Inc
174% Upside
QURE
Uniqure NV
150% Upside
CLDX
Celldex Therapeutics Inc
206% Upside

Revenue
Forecast

Revenue Estimate
Mesoblast Ltd

For the last 8 years the compound annual growth rate for Mesoblast Ltd's revenue is -22%. The projected CAGR for the next 3 years is 250%.

-22%
Past Growth
250%
Estimated Growth
Estimates Accuracy
-11%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Mesoblast Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-14%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Mesoblast Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
N/A
Average
What are analyst estimates?

See Also

Summary
MSB intrinsic value, competitors valuation, and company profile.
DCF Valuation
MSB stock valuation using Discount Cash Flow valuation method.
Relative Valuation
MSB stock valuation using valuation multiples.
Wall Street Estimates
MSB price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
MSB stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is MSB's stock price target?
Price Target
2.958 AUD

According to Wall Street analysts, the average 1-year price target for MSB is 2.958 AUD with a low forecast of 2.424 AUD and a high forecast of 3.57 AUD.

What is Mesoblast Ltd's Revenue forecast?
Projected CAGR
250%

For the last 8 years the compound annual growth rate for Mesoblast Ltd's revenue is -22%. The projected CAGR for the next 3 years is 250%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 251,800+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.